A new study led by researchers at Yale Cancer Center and the University of Maryland shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumor. The findings were published in Nature.
Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types. Their findings, published the February 17 issue of CELL, provide a potential roadmap for metastatic tumor formation that could be used to design therapies to improve the treatment of metastasized patients.
Scientists at Roswell Park Comprehensive Cancer Center have identified a potential new target for the treatment of pancreatic cancer. The study, published today in Cancer Cell, outlines the team’s discovery of a fungus-activated pathway that fuels the production of a molecule present in cancerous cells in the pancreas, opening a possible new treatment avenue for patients with this devastating disease.
Physician researchers from UT Southwestern Medical Center have developed an innovative nanotherapeutic drug that prevents cancer from spreading to the liver in mice.
Endometrial cancer is the most common cancer of the female reproductive system. Patients who have active immune responses against cancer cells tend to have better outcomes, but much of what is known focuses on only one type of immune cell called T cells. In a new study published in Cancer Research, Moffitt Cancer Center researchers provide insight on the role of B cell immunity in endometrial cancer.
Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures. However, little is known about how tertiary lymphoid structures form. In a new article published in Immunity, Moffitt Cancer Center researchers report on the molecular and cellular mechanisms that control tertiary lymphoid structure formation within tumors.
Johns Hopkins Medicine researchers have developed a color-coded test that quickly signals whether newly developed nanoparticles — ultra small compartments designed to ferry medicines, vaccines and other therapies — deliver their cargo into target cells. The new testing tool, engineered specifically to test nanoparticles, could advance the search for next-generation biological medicines.
Lung cancer is one of the most common cancers in the world and is a leading cause of cancer-related death in men and women in the United States according to the American Cancer Society. Although cigarette smoking is the main cause of lung cancer and quitting would prevent a large number of lung cancer cases, it wouldn't prevent all of them.
An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer. The study, published today in Cell Reports, provides insight into how loss or mutation of the NCOR2 gene accelerates the progression of prostate cancer to a more lethal form of the disease.
Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma. Their findings were published as a case study in Nature Medicine in December.
Roswell Park Comprehensive Cancer Center is one of three lead centers part of an international multicenter team that has recently been awarded $10 million to study how tobacco control policies impact smoking, vaping and the use of other nicotine products.
UC San Diego researchers identify new strategy to improve efficacy of immunotherapy on resistant liver cancers.
Ever since the first barcode appeared on a pack of chewing gum in 1974, the now-ubiquitous system has enabled manufacturers, retailers and consumers to quickly and effectively identify, characterize, locate and track products and materials. In a paper first posted online Nov. 26, 2021, in the journal Cell, researchers at Johns Hopkins Medicine and The Johns Hopkins University demonstrate how they can do the same thing at the molecular level, studying the ways cancer cells “talk” with one another.
The National Cancer Institute has awarded Mount Sinai researchers $3.15 million in grant funding to assess the potential of a multidisciplinary drug development platform to identify new biological targets for precision-based therapeutics for hepatocellular carcinoma (HCC). The platform includes precision mouse models, tumor 3D organoids, and a proprietary library of small molecule inhibitors.
Melanoma researchers at Huntsman Cancer Institute published a study that gives a new explanation of what causes moles to change into melanoma. These findings pave the way for more research into how to reduce the risk of melanoma, delay development, and detect melanoma early.
A new study from the University of Michigan Health Rogel Cancer Center finds circulating tumor DNA, or ctDNA, levels can predict as early as two weeks after starting treatment which patients are likely to have good outcomes. At the same time, specialized MRI and PET scans two weeks after starting chemoradiation also correlated with outcomes.
An Indiana University cancer researcher is leading an $11.4 million grant from the National Cancer Institute in which he and others across the country will work on identifying new treatments for tumors that develop in children, adolescents and adults with a common genetic condition.
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. They also identified potential targeted treatments based on the findings, as reported in Science Advances in November.
More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment with targeted therapies.
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania. The study, published in JAMA Oncology, suggests that the positive results for phase 3 clinical trial participants receiving ICI treatment may not translate to patients who are ineligible for trials due to factors such as organ dysfunction.
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
Exposure in utero to a drug used to prevent miscarriage can lead to an increased risk of developing cancer, according to researchers at The University of Texas Health Science Center at Houston (UTHealth Houston).
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
Leptin, a molecule produced by fat cells, appears to cancel out the effects of the estrogen-blocking therapy tamoxifen, a drug commonly used to treat and prevent breast cancers, suggests a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.
A new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors. The scientists found that prostate cancers develop ways to shut down this RNA molecule to allow themselves to grow.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, according to a new study by Dana-Farber Cancer Institute investigators.
University of California San Diego researchers describe how a pair of fundamental genetic and cellular processes — aneuploidy and unfolded protein response — are exploited by cancer cells to promote tumor survival and growth.
Washington University School of Medicine in St. Louis is joining the National Institutes of Health’s (NIH) new research network focused on the study of senescent cells, a rare and important population of cells that is difficult to study but vital for understanding aging and the diseases of aging, including cancer and neurodegeneration. The goal is to help researchers develop new therapies that target cellular senescence to prevent or treat such diseases and improve human health.
How cancers metastasize remains poorly understood. The process begins when cancer cells break off from a tumor and invade blood and lymphatic vessels, the body’s alleyways. But studying invasion - typically a microscopic process - is challenging.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston (UTHealth Houston).
If Black women begin mammography screening every other year starting at age 40, breast cancer deaths could be reduced by 57 percent compared to starting screening 10 years later — as is currently recommended by some organizations — according to analyses conducted by a modeling team that is part of the Cancer Intervention and Surveillance Modeling Network (CISNET), funded by the National Cancer Institute.
Researchers at Moffitt Cancer Center are trying to improve the personalization of radiation therapy through computer modeling. In a new study published in the journal Neoplasia, they model how interactions between cancer cells and immune cells, and their subsequent responses to radiation, impact the tumor. They propose their model may help to predict how patients respond to radiation therapy.
An international research team has found a small-molecule inhibitor that was able to suppress tumor growth in animal models of a childhood glioma — offering new hope toward developing therapies.
The National Cancer Institute has recognized Markus Müschen, MD, PhD, with its Outstanding Investigator Award.
Dr. Alice Soragni of the UCLA Jonsson Comprehensive Cancer Center has received a $2.5 million grant from the National Cancer Institute to develop lab-grown mini tumors that can help identify treatments for rare types of neuroendocrine cancer.
The National Cancer Institute renewed the “comprehensive” designation of the UC Davis Comprehensive Cancer Center in recognition of its breadth and depth in cancer research, clinical care, cancer control and population sciences.
Researchers and data scientists at UT Southwestern Medical Center and MD Anderson Cancer Center have developed an artificial intelligence technique that can identify which cell surface peptides produced by cancer cells called neoantigens are recognized by the immune system.
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
The Coriell Institute for Medical Research and Van Andel Institute (VAI) have been awarded a prestigious Specialized Programs of Research Excellence (or SPORE) grant from the National Cancer Institute (award P50CA254897). The five-year grant valued at an estimated $12.4 million will support nearly 20 scientists as they work to improve epigenetic therapies for cancer. The project is co-led by Coriell’s President and CEO Jean-Pierre Issa, MD, Van Andel Institute’s Chief Scientific Officer Peter A. Jones, PhD, DSc (hon), and Johns Hopkins University and VAI’s Stephen Baylin, MD.
The Wistar Institute and Penn Medicine have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.
Cleveland Clinic has established a center focused on the diagnosis, care, and research of young-onset colorectal cancer.
The University of New Mexico Comprehensive Cancer Center has once again been awarded the highest designation and rating in the United States for cancer treatment and research programs.
Moffitt Cancer Center has once again been awarded the National Cancer Institute’s highest designation, Comprehensive Cancer Center, with its highest ranking ever.
Findings from St. Jude Children’s Research Hospital show how control of transcription factors by a common tumor suppressor gene may provide a therapeutic opportunity in a type of childhood cancer.
A family of proteins best known for their role in diminishing HIV infectivity may have the goods to outwit other emerging and re-emerging viruses, scientists have found.
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer.
Researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center are combining efforts after together securing a nearly $9 million grant from the National Cancer Institute (NCI) to develop new and better treatments for ovarian cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right